Anti Mullerian Hormone (AMH) at Test Zone Diagnostic Center

Anti Mullerian Hormone (AMH) at Test Zone Diagnostic Center

The Anti Mullerian Hormone (AMH) test is a sophisticated diagnostic tool used primarily to evaluate a woman’s ovarian reserve and overall reproductive health. AMH is a glycoprotein hormone produced by the granulosa cells of preantral and small antral follicles in the ovaries. Unlike other reproductive hormones, such as follicle-stimulating hormone (FSH) and estradiol, which fluctuate significantly throughout the menstrual cycle, AMH levels remain remarkably stable. This stability makes it an invaluable marker in clinical endocrinology and reproductive medicine, allowing for testing at any point during the menstrual cycle. At Test Zone Diagnostic Center in Lahore, Pakistan, we utilize state-of-the-art automated laboratory technology to deliver highly precise and reliable AMH measurements, helping patients and clinicians make informed decisions regarding fertility, family planning, and endocrine disorders.

Ovarian reserve refers to the remaining pool of viable oocytes in the ovaries. As women age, this pool naturally declines in both quantity and quality. By measuring the concentration of AMH in the bloodstream, healthcare providers can estimate the relative size of this remaining follicle pool. This assessment is crucial for women planning delayed childbearing, those experiencing difficulties conceiving, or individuals preparing for assisted reproductive technologies (ART) such as In Vitro Fertilization (IVF). Beyond fertility, the AMH test serves as a vital diagnostic aid in evaluating conditions like Polycystic Ovary Syndrome (PCOS), diagnosing Premature Ovarian Insufficiency (POI), and monitoring specific ovarian tumors. At Test Zone Diagnostic Center, we are committed to providing accurate diagnostic insights with the highest standards of clinical care, ensuring that every patient receives clear, actionable, and timely results.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy, patients should follow specific preparation guidelines before undergoing the Anti Mullerian Hormone (AMH) test at Test Zone Diagnostic Center. Please review the following instructions:

• No Fasting Required: You do not need to fast before this test. You may eat and drink normally prior to your appointment.
• Timing: Because AMH levels remain stable throughout the menstrual cycle, the blood sample can be collected on any day of your cycle, including during your period.
• Medication Review: Inform your healthcare provider and our laboratory staff about all medications, supplements, and hormonal contraceptives you are currently taking.
• Hormonal Contraceptives: Oral contraceptive pills, patches, or vaginal rings can temporarily suppress ovarian activity and may artificially lower AMH levels. Your physician may advise waiting a specific period after discontinuing these before testing.
• Biotin Warning: High doses of biotin (Vitamin B7), commonly found in hair, skin, and nail supplements, can interfere with laboratory immunoassay platforms. It is recommended to avoid biotin supplements for at least 72 hours prior to your blood draw.
• Hydration: Drink plenty of water before the procedure, as proper hydration makes venipuncture easier and more comfortable.

During the Procedure

When you arrive at Test Zone Diagnostic Center for your AMH test, you will experience a streamlined, professional, and comfortable sample collection process:

• Patient Identification: Our phlebotomist will verify your identity and explain the procedure to you.
• Positioning: You will be seated comfortably in a specialized blood collection chair.
• Aseptic Technique: The phlebotomist will inspect your arm to locate a suitable vein, typically in the antecubital fossa (inner elbow). The skin over the selected vein will be thoroughly cleansed with an antiseptic swab.
• Venipuncture: A sterile, single-use needle will be gently inserted into the vein. You may feel a brief, mild pinch or stinging sensation.
• Sample Collection: A small volume of blood will be drawn into a specialized serum separator tube (SST). The entire collection process takes less than two minutes.
• Post-Draw Care: The needle will be removed, and the phlebotomist will apply gentle pressure to the site with a sterile cotton ball, followed by a small adhesive bandage to prevent bruising.
• Safety and Comfort: All materials used are sterile and disposable, ensuring zero risk of cross-contamination. You can resume your normal daily activities immediately after the procedure.

When is an Anti Mullerian Hormone (AMH) Test Performed?

Assessment of Ovarian Reserve

The primary clinical indication for an AMH test is the assessment of a woman’s ovarian reserve. This is highly relevant for women who are planning to delay pregnancy for career or personal reasons, or those who have been actively trying to conceive without success. By determining the remaining egg supply, the test helps reproductive endocrinologists estimate the reproductive window, allowing patients to make informed decisions regarding family planning, egg freezing (oocyte cryopreservation), or immediate fertility treatments.

Evaluation of Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Women with PCOS typically have an abnormally high number of small, early-stage antral follicles. Because these follicles are the primary source of AMH, patients with PCOS often exhibit significantly elevated serum AMH levels. Measuring AMH helps clinicians support a diagnosis of PCOS, especially when pelvic ultrasound imaging is inconclusive or difficult to perform.

Predicting IVF and Assisted Reproduction Outcomes

In assisted reproductive technology (ART), the AMH test is a critical tool for predicting how a patient’s ovaries will respond to controlled ovarian stimulation. High AMH levels suggest a strong response, alerting the fertility specialist to use lower doses of stimulating hormones to avoid Ovarian Hyperstimulation Syndrome (OHSS)—a potentially dangerous complication. Conversely, low AMH levels indicate a potential poor response, allowing clinicians to customize stimulation protocols to maximize oocyte yield safely.

Investigation of Premature Ovarian Insufficiency (POI)

Premature Ovarian Insufficiency (POI), or premature ovarian failure, occurs when a woman’s ovaries stop functioning normally before the age of 40. Symptoms include irregular periods, amenorrhea, hot flashes, and mood changes. An AMH test is highly valuable in this context; extremely low or undetectable AMH levels in a young woman support a diagnosis of POI, enabling early clinical intervention, hormone replacement therapy (HRT) to protect bone health, and urgent fertility preservation counseling.

Monitoring Ovarian Granulosa Cell Tumors

Granulosa cell tumors are rare, slow-growing ovarian cancers that arise from the sex cord-stromal cells. Because these tumor cells retain the functional capacity of normal granulosa cells, they secrete high levels of AMH. In patients diagnosed with these tumors, baseline AMH levels are elevated. Following surgical removal of the tumor, AMH levels should drop to undetectable levels. Serial AMH testing is therefore utilized as a highly sensitive tumor marker to monitor for cancer recurrence or residual disease.

What Does an Anti Mullerian Hormone (AMH) Detect?

The Anti Mullerian Hormone (AMH) test is a highly sensitive biomarker that provides detailed clinical insights into ovarian biology and pathology. Specifically, the test detects and evaluates:

• Age-appropriate ovarian reserve indicating normal reproductive potential.
• Diminished ovarian reserve (DOR) suggesting a reduced pool of remaining oocytes.
• Severely depleted ovarian reserve indicative of impending natural menopause.
• High ovarian reserve strongly associated with Polycystic Ovary Syndrome (PCOS).
• Elevated risk of developing Ovarian Hyperstimulation Syndrome (OHSS) during fertility treatments.
• Poor ovarian response to gonadotropin stimulation in assisted reproductive cycles.
• Premature Ovarian Insufficiency (POI) in women under the age of 40.
• Transition phase into perimenopause characterized by declining follicle counts.
• Postmenopausal status indicated by undetectable or near-zero hormone levels.
• Presence of active ovarian granulosa cell tumors (sex cord-stromal tumors).
• Recurrence of granulosa cell tumors during post-treatment surveillance.
• Completeness of surgical resection of AMH-secreting ovarian neoplasms.
• Gonadotoxic damage to ovaries following chemotherapy or pelvic radiation therapy.
• Iatrogenic reduction in ovarian reserve post-gynecological surgeries, such as cystectomy for endometriomas.
• Hypogonadotropic hypogonadism leading to secondary suppression of ovarian function.
• Streak ovaries or gonadal dysgenesis associated with genetic conditions like Turner syndrome.
• Assessment of ovarian reserve prior to elective social egg freezing.
• Impact of severe endometriosis on healthy ovarian tissue and follicular reserve.
• Baseline reproductive capacity during preconception counseling and health screening.
• Discrepancy between chronological age and biological ovarian age.
• Efficacy of medical or lifestyle interventions in managing PCOS-related follicular excess.
• High-responder status in IVF, allowing for proactive protocol modifications.
• Congenital absence of functional ovarian tissue (bilateral anorchia equivalent in females).
• Evaluation of ambiguous genitalia or intersex conditions in pediatric endocrinology.
• Assessment of testicular function and presence of viable testicular tissue in cryptorchid males.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for diagnostic results can be an anxious time for patients. We are committed to providing rapid, accurate, and reliable reporting. The turnaround time for the Anti Mullerian Hormone (AMH) test is typically within 24 to 48 hours from the time of sample collection. Once our laboratory specialists verify and authorize the results, patients receive an automated SMS notification. Reports can be accessed securely online through our patient portal, downloaded via our official mobile application, or collected in person at our diagnostic center in Lahore. This seamless digital access ensures that you can promptly share your results with your referring physician for timely clinical decision-making.

Anti Mullerian Hormone (AMH) Findings Overview

The following table provides a general clinical guide to interpreting Anti Mullerian Hormone (AMH) levels across different clinical scenarios:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Ovarian Reserve (Age 20-29)	2.0 – 6.8 ng/mL (Optimal Reserve)	< 1.0 ng/mL (Diminished), > 6.8 ng/mL (High/PCOS)
Ovarian Reserve (Age 30-34)	1.5 – 4.0 ng/mL (Adequate Reserve)	< 0.8 ng/mL (Low Reserve), Elevated (PCOS)
Ovarian Reserve (Age 35-39)	1.0 – 3.0 ng/mL (Age-Appropriate)	< 0.5 ng/mL (Severely Diminished Reserve)
Ovarian Reserve (Age 40-44)	0.2 – 1.5 ng/mL (Expected Decline)	< 0.1 ng/mL (Impending Menopause)
Ovarian Reserve (Age >45)	< 0.5 ng/mL (Transition Phase)	Undetectable (Postmenopausal Baseline)
PCOS Evaluation	Normal follicular distribution	> 5.0 – 10.0 ng/mL (Polycystic Ovaries)
Granulosa Cell Tumor Marker	Undetectable/Low (post-menopause/resection)	Significantly elevated (Recurrence/Active tumor)
Ovarian Stimulation Response	Moderate response predicted (1.0-3.5 ng/mL)	< 0.5 ng/mL (Poor responder), > 3.5 ng/mL (Hyper-responder/OHSS risk)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Anti Mullerian Hormone (AMH)?

• Experienced healthcare professionals: Our laboratory is staffed by highly qualified pathologists, technologists, and phlebotomists dedicated to diagnostic excellence.
• Patient-focused care: We prioritize patient comfort, safety, and confidentiality at every stage of the diagnostic process.
• Quality diagnostic services: We adhere to stringent quality control protocols to ensure the highest accuracy and reliability of all test results.
• Professional reporting: Our comprehensive reports provide clear, detailed, and easy-to-understand diagnostic data for patients and clinicians.
• Modern diagnostic approach: We utilize state-of-the-art laboratory equipment and fully automated immunoassay platforms.
• Comfortable environment: Our diagnostic center in Lahore offers a clean, welcoming, and stress-free environment for sample collection.
• Convenient location: Easily accessible facilities with ample parking and comfortable waiting areas for patients.
• Commitment to accurate diagnosis: We employ rigorous internal and external quality assurance programs to maintain international standards.